Researcher profile

Alex Ocampo

Alex Ocampo contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 15 - UnverifiedVerification L1Unclaimed author
3works
0followers
2topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

3 published item(s)

preprint2026arXiv

Revealing the Truth: Calculating True Values in Causal Inference Simulation Studies via Gaussian Quadrature

Simulation studies are used to understand the properties of statistical methods. A key luxury in many simulation studies is knowledge of the true value (i.e. the estimand) being targeted. With this oracle knowledge in-hand, the researcher conducting the simulation study can assess across repeated realizations of the data how well a given method recovers the truth. In causal inference simulation studies, the truth is rarely a simple parameter of the statistical model chosen to generate the data. Instead, the estimand is often an average treatment effect, marginalized over the distribution of confounders and/or mediators. Luckily, these variables are often generated from common distributions such as the normal, uniform, exponential, or gamma. For all these distributions, Gaussian quadratures provide efficient and accurate calculation for integrands with integral kernels that stem from known probability density functions. We demonstrate through four applications how to use Gaussian quadrature to accurately and efficiently compute the true causal estimand. We also compare the pros and cons of Gauss-Hermite quadrature to Monte Carlo integration approaches, which we use as benchmarks. Overall, we demonstrate that the Gaussian quadrature is an accurate tool with negligible computation time, yet is underused for calculating the true causal estimands in simulation studies.

preprint2022arXiv

Single-World Intervention Graphs for Defining, Identifying, and Communicating Estimands in Clinical Trials

Confusion often arises when attempting to articulate target estimand(s) of a clinical trial in plain language. We aim to rectify this confusion by using a type of causal graph called the Single-World Intervention Graph (SWIG) to provide a visual representation of the estimand that can be effectively communicated to interdisciplinary stakeholders. These graphs not only display estimands, but also illustrate the assumptions under which a causal estimand is identifiable by presenting the graphical relationships between the treatment, intercurrent events, and clinical outcomes. To demonstrate its usefulness in pharmaceutical research, we present examples of SWIGs for various intercurrent event strategies specified in the ICH E9(R1) addendum, as well as an example from a real-world clinical trial for chronic pain. Latex code to generate all the SWIGs shown is this paper is made available. We advocate clinical trialists adopt the use of SWIGs in their estimand discussions during the planning stages of their studies.

preprint2019arXiv

Identifying Treatment Effects using Trimmed Means when Data are Missing Not at Random

Patients often discontinue treatment in a clinical trial because their health condition is not improving. Consequently, the patients still in the study at the end of the trial have better health outcomes on average than the initial patient population would have had if every patient had completed the trial. If we only analyze the patients who complete the trial, then this missing data problem biases the estimator of a medication's efficacy because study outcomes are missing not at random (MNAR). One way to overcome this problem - the trimmed means approach for missing data - sets missing values as slightly worse than the worst observed outcome and then trims away a fraction of the distribution from each treatment arm before calculating differences in treatment efficacy (Permutt 2017, Pharmaceutical statistics 16.1:20-28). In this paper we derive sufficient and necessary conditions for when this approach can identify the average population treatment effect in the presence of MNAR data. Numerical studies show the trimmed means approach's ability to effectively estimate treatment efficacy when data are MNAR and missingness is strongly associated with an unfavorable outcome, but trimmed means fail when data are missing at random (MAR) when the better approach would be to multiply impute the missing values. If the reasons for discontinuation in a clinical trial are known analysts can improve estimates with a combination of multiple imputation (MI) and the trimmed means approach when the assumptions of each missing data mechanism hold. When the assumptions are justifiable, using trimmed means can help identify treatment effects notwithstanding MNAR data.